A Psychometric Analysis of the Revised Child Anxiety and Depression Scales—Parent Version in a School Sample

Ebesutani, Chad; Chorpita, Bruce F.; Higa-McMillan, Charmaine K.; Nakamura, Brad J.; Regan, Jennifer; Lynch, Roxanna

doi:10.1007/s10802-010-9460-8

Cited by 81 publications

(73 citation statements)

References 46 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Higher scores reflect greater symptom severity. The RCADS-P contains the same six subscales as the RCADS, and has previously shown good psychometric properties with school-based (Ebesutani et al, 2011) and clinical (Ebesutani et al, 2010) CBCL for ages 6 to 18. The CBCL (Achenbach & Rescorla, 2001) is a 113-item, parent-report of a child/adolescent's broad internalizing and externalizing behaviors.…”

Section: Rcads-parent Versionmentioning

confidence: 99%

Anxiety-Disordered Adolescents With and Without a Comorbid Depressive Disorder

Queen

Ehrenreich–May

2013

Journal of Emotional and Behavioral Disorders

View full text Add to dashboard Cite

There is a high degree of comorbidity between anxiety and depressive disorders among treatment-seeking adolescents. Comorbid youth often present with greater diagnostic severity, worse social functioning, and more severe anxiety and depressive symptoms, compared with anxiety-disordered youth without depression. However, the degree to which these populations may differ in underlying affect and emotion regulation (ER) is largely unknown. This study compared 44 anxietydisordered adolescents (ages 12-18 years) with a comorbid depressive disorder (ANX + DEP) and 32 anxiety-disordered adolescents without a comorbid depressive disorder (ANX) on several clinical and emotion-related variables. Results indicated that ANX + DEP adolescents were assigned higher clinician-rated diagnostic severity ratings, and reported greater functional impairment and more severe social anxiety and depressive symptoms, compared with ANX adolescents. In addition, ANX + DEP adolescents demonstrated higher levels of negative affect, lower levels of positive affect, and poorer self-reported and parent-reported ER. Implications for assessment and treatment, as well as directions for future research, are discussed.

show abstract

Section: Rcads-parent Versionmentioning

confidence: 99%

Anxiety-Disordered Adolescents With and Without a Comorbid Depressive Disorder

Queen

Ehrenreich–May

2013

Journal of Emotional and Behavioral Disorders

View full text Add to dashboard Cite

show abstract

“…Prior to each youth beginning therapy, a team comprising doctorate-level study staff, in conjunction with the Principal Investigator, determined youths’ principal problem area (i.e., anxiety, depression, or conduct) via scores from youth- and caregiver-identified top problems, as well as youth- and caregiver-reports on the Strengths and Difficulties Questionnaire (Goodman, 2001), Revised Child Anxiety and Depression Scales (Chorpita, Moffitt, & Gray, 2005; Ebesutani, Bernstein, Nakamura, Chorpita, & Weisz, 2010, 2011; Ebesutani, Tottenham, & Chorpita, 2015), and UCLA PTSD Reaction Index (Steinberg, Brymer, Decker, & Pynoos, 2004). Initial treatment selection decisions were based off of the protocol flowchart indicated for youths’ principal problem area (e.g., providers treating youths with a principal problem of anxiety were expected to deliver rapport-building practices and to provide basic information about anxiety in the first session).…”

Section: Methodsmentioning

confidence: 99%

Community-Based Providers’ Selection of Practices for Children and Adolescents With Comorbid Mental Health Problems

Park

Moskowitz

Chorpita

2016

Journal of Clinical Child & Adolescent Psychology

Self Cite

View full text Add to dashboard Cite

The goal of this study is to explore providers’ patterns of implementation by investigating how community mental health providers selected therapy practice modules from a flexible, modular evidence-based treatment working with youths with comorbid mental health problems. Data were obtained from 57 youths, 5–15 years old, presenting with anxiety, depressive, and/or conduct problems and their 27 providers during their participation in an effectiveness trial involving a modular evidence-based treatment. Although all youths evidenced clinically elevated symptomatology in at least two problem areas, providers targeted youths’ comorbid problems with only about half of their study cases. Practice modules indicated for youths’ comorbid problems were typically used less frequently and with less depth relative to practice modules indicated for youths’ principal clinical problem and were often transdiagnostic in nature (i.e., designed to target more than one problem area). To determine whether providers’ decisions to target youths’ comorbid problems were systematic, multilevel, logistic regression analyses were conducted and revealed that youths’ pretreatment characteristics and time in therapy influenced providers’ patterns of module selection. Providers tend to use, but not exploit, the flexibility allowed by modular EBTs and to focus treatment on youths’ principal presenting problem. In addition, providers appear to make these practice choices in a systematic and rational manner, and whether and which choices are associated with improved outcomes is an important area of future study.

show abstract

“…Both versions are identical in question content, number, and subscale classification. The RCADS has good psychometric properties with high internal consistency and convergent validity, and has been shown to accurately assess anxiety and depressive symptoms both in clinical and school-based youth (Chorpita et al, 2005;Ebesutani et al, 2010;Ebesutani et al, 2011).…”

Section: Revised Child Anxiety and Depression Scale (Rcads) Youth Anmentioning

confidence: 99%

affron®, a standardised extract from saffron (Crocus sativus L.) for the treatment of youth anxiety and depressive symptoms: A randomised, double-blind, placebo-controlled study

Lopresti

Drummond

Inarejos-García³

et al. 2018

Journal of Affective Disorders

View full text Add to dashboard Cite

Esta es la versión de autor del artículo publicado en: This is an author produced version of a paper published in:Journal of Affective Disorders 232 (2018) However, this is the first study examining its mood-related effects in teenagers. MethodsIn this 8-week, randomised, double-blind, placebo-controlled study, youth aged 12 to 16 years, with mild-to-moderate anxiety or depressive symptoms were given tablets containing placebo or a saffron extract (affron ® , 14mg b.i. d). The youth and parent versions of the Revised ChildAnxiety and Depression Scale (RCADS) were used as outcome measures.Results 80 participants were enrolled and 68 completed the study. Based on youth self-reports, affron ® was associated with greater improvements in overall internalising symptoms (p = .049), separation anxiety (p = .003), social phobia (p = .023), and depression (p = .016). Total internalising scores decreased by an average of 33% compared to 17% in the placebo group (p=.029). However, parental reports of improvements were inconsistent as mean improvements in RCADS scores were greater in the saffron group (40% vs 26%) (p=.026), although no other significant differences were identified. affron ® was well-tolerated and there was a trend of reduced headaches in participants on the active treatment.Limitations: The use of a self-report instrument, limited study duration, single treatment dose, and non-clinical sample used in this study limit the generalisability of study findings. ConclusionThe administration of a standardised saffron extract (affron ® ) for 8 weeks improved anxiety and depressive symptoms in youth with mild-to-moderate symptoms, at least from the perspective of the adolescent. However, these beneficial effects were inconsistently corroborated by parents.

show abstract

A Psychometric Analysis of the Revised Child Anxiety and Depression Scales—Parent Version in a School Sample

Cited by 81 publications

References 46 publications

Anxiety-Disordered Adolescents With and Without a Comorbid Depressive Disorder

Anxiety-Disordered Adolescents With and Without a Comorbid Depressive Disorder

Community-Based Providers’ Selection of Practices for Children and Adolescents With Comorbid Mental Health Problems

affron®, a standardised extract from saffron (Crocus sativus L.) for the treatment of youth anxiety and depressive symptoms: A randomised, double-blind, placebo-controlled study

Contact Info

Product

Resources

About